The Healthcare M&A Wave
In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.
EDIT - Editas Medicine, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$5.00
DETAILS
HIGH:
$6.00
LOW:
$4.00
MEDIAN:
$5.00
CONSENSUS:
$5.00
UPSIDE:
33.33%
Stock News
CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026?
One company dominates with an approved therapy, while the other bets on in vivo innovation. See how their financials and risk profiles stack up for 2026.
Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference
CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it will now present at the 2026 Jefferies Global Healthcare Conference at 2:00 p.m. ET on Thursday, June 4, 2026.
Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering
CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced the pricing of an underwritten public offering of 55,555,556 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 55,555,556 shares of common stock (or pre-funded warrants in lieu thereof). Each share of common stock and accompanying common stock warrant are being sold together at a combined public offering price of $2.25. The aggregate gross proceeds from the offering are expected to be approximately $125.0 million (assuming no exercise of the common stock warrants), before deducting underwriting discounts and commissions and offering expenses. If all of the common stock warrants are exercised at their exercise price, the Company would receive additional gross proceeds from the offering of approximately $194.4 million before deducting underwriting discounts and commissions and offering expenses.
Editas Medicine Announces Proposed Public Offering
CAMBRIDGE, Mass. , May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced that it has commenced an underwritten public offering of its common stock (or pre-funded warrants to purchase shares of common stock in lieu thereof) and accompanying warrants to purchase shares of common stock (or pre-funded warrants in lieu thereof).
Editas Medicine Announces Proposed Public Offering
CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced that it has commenced an underwritten public offering of its common stock (or pre-funded warrants to purchase shares of common stock in lieu thereof) and accompanying warrants to purchase shares of common stock (or pre-funded warrants in lieu thereof). All of the securities in the offering are to be sold by Editas Medicine.
Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress
Single dose of EDIT-401 achieved ~90% or greater mean reductions in LDL-C, Lp(a), and ApoB in non-human primates Data reinforce differentiated LDLR upregulation approach with rapid, dose-dependent effects on multiple atherogenic lipoproteins Company on track to submit CTN by mid-2026 for EDIT-401 and achieve early in vivo human proof-of-concept data by the end of 2026 CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, presented new preclinical data for EDIT-401, its lead in vivo development candidate, in an oral presentation at the 94th European Atherosclerosis Society (EAS) Congress in Athens, Greece on May 25, 2026.
Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting
New data demonstrate promising preclinical safety profile and durable LDL-C lowering of ≥90% with single dose of EDIT-401 in non-human primates through ~6 months New data demonstrate promising preclinical safety profile and durable LDL-C lowering of ≥90% with single dose of EDIT-401 in non-human primates through ~6 months
Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting
CAMBRIDGE, Mass. , May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical data supporting the continued advancement of Editas' lead in vivo development candidate, EDIT-401, and its potential as a one-time treatment for hyperlipidemia, as well as the broader potential of the Company's differentiated upregulation strategy.
EDIT's Q1 Loss Narrower Than Expected, Pipeline in Focus
Editas narrows Q1 loss as costs fall, but revenues drop sharply. Pipeline focus shifts to in vivo gene editing and lead candidate EDIT-401.
Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates
Editas Medicine (EDIT) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.43 per share a year ago.
Editas Medicine Announces First Quarter 2026 Results and Business Updates
EDIT-401, which demonstrated >90% mean LDL-C reduction in preclinical studies, on track to achieve early human proof-of-concept data by year-end 2026 Company to present new EDIT-401 preclinical data at upcoming scientific meetings, including data showing significant reductions in Lp(a) and ApoB in non-human primates at the 94th EAS Congress U.S. Patent and Trademark Office reaffirmed prior decision in favor of the Broad Institute in CRISPR/Cas9 interference CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today reported financial results for the first quarter 2026 and provided business updates.
Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences
CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that five abstracts have been accepted for presentation, including one oral presentation and two poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting, one oral presentation at TIDES USA 2026: Oligonucleotide and Peptide Therapeutics Conference, and one oral presentation at the 94th European Atherosclerosis Society (EAS) Congress. The Company is presenting new preclinical data, including data to support the potential of EDIT-401, its lead in vivo development candidate, to be a transformative therapy for people living with hyperlipidemia.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Average Recommendation of “Moderate Buy” from Analysts
Shares of Editas Medicine, Inc. (NASDAQ: EDIT - Get Free Report) have received an average rating of "Moderate Buy" from the eight brokerages that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, five have issued a buy rating and one has assigned
Editas (EDIT) Up 3.8% Since Last Earnings Report: Can It Continue?
Editas (EDIT) reported earnings 30 days ago. What's next for the stock?
JPMorgan Chase & Co. Has $2.85 Million Position in Editas Medicine, Inc. $EDIT
JPMorgan Chase and Co. cut its holdings in Editas Medicine, Inc. (NASDAQ: EDIT) by 23.0% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 820,667 shares of the company's stock after selling 245,055 shares during the period. JPMorgan Chase
Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference
CAMBRIDGE, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that the U.S. Patent and Trademark Office reaffirmed the Patent Trial and Appeal Board's (PTAB's) previous decision favoring the Broad Institute in the U.S. patent interference involving specific patents for CRISPR/Cas9 editing in human cells between the University of California, the University of Vienna, and Emmanuelle Charpentier (collectively, CVC) and the Broad Institute, Massachusetts Institute of Technology (MIT), and Harvard University (collectively, Broad).
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Consensus Rating of “Moderate Buy” from Analysts
Shares of Editas Medicine, Inc. (NASDAQ: EDIT - Get Free Report) have been given a consensus rating of "Moderate Buy" by the eight analysts that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, five have assigned a buy rating and one
Is Editas Medicine Going to $0?
Editas Medicine has been on fire over the trailing-12-month period. However, the stock has been crushed since 2021, as it has faced plenty of setbacks.
Price Targets
Editas Medicine price target raised to $4 from $3.50 at Chardan
$4.00
(was $3.04)
Chardan Capital
Baird Reiterates Outperform Rating on Editas Medicine (EDIT) following earnings
$6.00
(was $2.32)
Robert W. Baird
Editas Medicine (EDIT) PT Lowered to $5 at Barclays
$5.00
(was $3.12)
Gena Wang
·
Barclays
Editas Medicine (EDIT) PT Lowered to $9 at Wells Fargo
$9.00
(was $3.29)
Yanan Zhu
·
Wells Fargo
Editas Medicine (EDIT) PT Lowered to $10 at Baird
$10.00
(was $3.29)
Joel Beatty
·
Robert W. Baird
Editas Medicine (EDIT) PT Lowered to $12 at Truist Securities
$12.00
(was $4.24)
Joon Lee
·
Truist Financial
BofA Securities Upgrades Editas Medicine (EDIT) to Buy
$15.00
(was $4.21)
Greg Harrison
·
Bank of America Securities
Editas Medicine (EDIT) PT Lowered to $7 at Evercore ISI
$7.00
(was $5.10)
Liisa Bayko
·
Evercore ISI
Morgan Stanley Upgrades Editas Medicine (EDIT) to Equalweight
$7.00
(was $5.04)
Matthew Harrison
·
Morgan Stanley
Stifel Upgrades Editas Medicine (EDIT) to Buy, 'Difficult To Justify Current Valuation'
$17.00
(was $6.92)
Dae Gon Ha
·
Stifel Nicolaus
Citigroup Initiates Coverage On Editas Medicine with Neutral Rating, Announces Price Target of $11
$11.00
(was $9.96)
Citigroup
Morgan Stanley Maintains Underweight on Editas Medicine, Lowers Price Target to $8
$8.00
(was $10.63)
Morgan Stanley
RBC Capital Maintains Sector Perform on Editas Medicine, Lowers Price Target to $14
$14.00
(was $11.01)
RBC Capital
Editas Medicine price target lowered to $35 from $80 at Truist
$35.00
(was $11.01)
Joon Lee
·
Truist Financial
Oppenheimer Downgrades Editas Medicine to Perform, Lowers Price Target to $12
$12.00
(was $11.01)
Oppenheimer
Credit Suisse Downgrades Editas Medicine to Neutral, Lowers Price Target to $13
$13.00
(was $11.01)
Credit Suisse
Chardan Capital Maintains Buy on Editas Medicine, Lowers Price Target to $35
$35.00
(was $11.01)
Chardan Capital
Morgan Stanley Sticks to Their Sell Rating for Editas Medicine (EDIT)
$24.00
(was $24.41)
Matthew Harrison
·
Morgan Stanley
Price Target Update
$44.00
(was $40.57)
Joel Beatty
·
Robert W. Baird
Editas' EDIT-101 topped bar seen by experts as FDA hurdle, says Truist
$80.00
(was $42.50)
Joon Lee
·
Truist Financial